Microbial consortium composed of Cellulomonas ZJW-6 and Acinetobacter DA-25 improves straw lignocellulose degradation.

In the present study, 27 bacterial strains were isolated from environmental samples and screened for higher lignocellulose-degrading efficiency. The best degrader was combined in pairs with 14 strains with high ß-glucosidase activity to formulate a consortium. Microbial consortium 625 showed high lignocellulose degradation efficiency. ZJW-6 with low ß-glucosidase activity and the best lignocellulose decomposer was identified as a member of Cellulomonas. Consortium 625 composed of ZJW-6 and DA-25, an Acinetobacter, showed the highest degradation rate (57.62%) under optimized conditions. The DA-25 filtrate promoted ZJW-6 growth, upregulating the activity of key lignocellulose-degrading enzymes, including ß-glucosidase, endoglucanase, xylanase, laccase, and lignin peroxidase. ZJW-6 and DA-25 worked in a subordination manner when co-cultivated. ZJW-6 acted as the major decomposer whose growth and enzymatic activities were promoted by DA-25. This study proposes a novel microbial consortium with improved lignocellulose degradation efficiency and reduce the C:N ratio of lignocellulose materials, which can enhance bioenergy production.

Recent advances in chiral liquid chromatography stationary phases for pharmaceutical analysis.

Chirality is a common phenomenon in nature. Different enantiomers of chiral drug compounds have obvious differences in their effects on the human body. Therefore, the separation of chiral drugs plays an extremely important role in the safe utilization of drugs. High-performance liquid chromatography (HPLC) is an effective tool for the separation and analysis of compounds, in which the chromatographic packing plays a key role in the separation. Chiral pharmaceutical separation and analysis in HPLC rely on chiral stationary phases (CSPs). Thus, various CSPs are being developed to meet the needs of chiral drug separation and analysis. In this review, recent developments in CSPs, including saccharides (cyclodextrin, cellulose, amylose and chitosan), macrocycles (macrocyclic glycopeptides, pillar[n]arene and polyamide) and porous organic materials (metal-organic frameworks, covalent organic frameworks, and porous organic cages), for pharmaceutical analysis in HPLC were summarized, the advantages and disadvantages of various stationary phases were introduced, and their development prospects were discussed.